Health In Tech reported Q1 2026 results on May 13 after the close, and the print hands short sellers exactly the kind of validation they've been building towards — revenue came in at $4.5M, a sharp miss against the $7.3M estimate, even as the company held its full-year sales guidance at $45–50M.
The short interest story has been building quietly but persistently for six weeks. Estimated shorts have nearly doubled over the past month, rising 91% to reach 1.98% of the free float by May 12. Most of that move was front-loaded: a large step-up appeared in late April, pushing short shares from the 340,000 range to over 820,000 in a single session on April 23. That rebuilt level has been sticky. The ORTEX short score has tracked the pressure, running in the low-to-mid 60s all month — not extreme, but elevated enough to rank in the 5th percentile for short score among peers, signalling this is a heavily watched name relative to its size. The borrow market has tightened in parallel: cost to borrow climbed to 17.4% annualised this week, up 16% over seven days, and while that has eased from April highs above 20%, the direction of travel has reversed back upward. Availability, meanwhile, has become genuinely constrained — availability has pulled well below the normal range, consistent with a small-float name where the lending pool is limited. Days to cover runs just over seven days on the official FINRA count, meaning any covering event takes time to unwind.
The analyst picture is thin but directionally positive, if stale by market-moving standards. Craig-Hallum initiated at Buy with a $4.00 target on April 20 — the only recent analyst action. The mean price target sits at $4.28 against a close of $1.52, implying over 180% implied upside. With a market cap of roughly $97M and a P/E multiple near 29x, the valuation is pricing in meaningful growth. The Q1 revenue miss — coming in 39% below the Street estimate — puts that growth thesis under pressure, though management's decision to affirm full-year guidance suggests the company views Q1 as a timing issue rather than a structural one. The EV/EBITDA multiple has been compressing on a seven-day basis, down over one turn this week.
Ownership is tightly concentrated, which amplifies moves in either direction. The top two holders — Tim Johnson and Julia Qian — together control roughly 68% of shares outstanding, leaving a small public float for institutional and short positioning to compete over. Qian added nearly 979,000 shares as recently as April 15, according to the latest filing. The April 24 prospectus filing to offer 5.6M shares by a selling stockholder adds another layer of supply overhang that the market must digest. Insider activity at the executive level was modest and directionally negative: the CEO, CFO, and a chief-level officer each sold small amounts at $1.50 on April 15, but the scale — combined value under $90,000 — keeps this closer to routine than alarming.
The last comparable earnings reaction offers context. The April 28 print produced a -3.3% next-day move and a modest +2.7% recovery over the following five days. The March 25 print was more severe: shares fell 11.5% on the day and 22% over the subsequent five sessions. A revenue miss of this magnitude — with guidance held but credibility now in question — sets up a different kind of scrutiny heading into the July 21 Q2 print, where the market will want to see whether the full-year run-rate can actually materialise from the $4.5M Q1 base.
What to watch: the pace at which short interest digests the post-earnings reaction, whether the selling stockholder prospectus translates into actual share supply, and whether Craig-Hallum revises its $4 target in light of the Q1 miss.
See the live data behind this article on ORTEX.
Open HIT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
